The Czech Centre for Phenogenomics (CCP) at the Institute of Molecular Genetics of the Czech Academy of Sciences, a member of the IMPC and INFRAFRONTIER research infrastructures, offers an exciting opportunity for a senior scientist and experienced scientific leader to head the Preclinical Evaluation Module (PEM).
The Czech Centre for Phenogenomics is a large research infrastructure of the Institute of Molecular Genetics of the Czech Academy of Sciences that supports biomedical and translational research through advanced disease-model generation, phenotyping, preclinical testing, and integrated analytical services. CCP provides academic and industrial users with expert support across the full pipeline from model design and biological characterization to treatment evaluation and interpretation of complex experimental outcomes.
CCP is now seeking a senior scientist and experienced scientific leader to head the Preclinical Evaluation Module (PEM). PEM is being developed as CCP’s dedicated module for integrated preclinical evaluation, bringing together specialist expertise in metabolomics, immunology, biochemistry and haematology, and histopathology, together with advanced study coordination and quality-management capacity for demanding research and contract studies, including projects for industrial and pharmaceutical partners. PEM interact also with other CCP modules, especially with the Phenotyping, Data Science Module, and others to provide comprehensive range of preclinical testing.
The Head of PEM will lead the scientific, strategic, and operational development of a module designed to translate samples, measurements, and experimental endpoints into biologically meaningful and decision-relevant evidence. PEM is intended to serve as CCP’s integrative evaluation platform for efficacy, safety, mechanism-of-action, biomarker, and pathology-oriented studies across a broad range of disease areas and intervention types.
As a Module Head within CCP’s organisation, the successful candidate will operate at the level of an independent Principal Investigator (PI) and will be responsible for the module’s scientific direction, service portfolio, outputs, quality standards, reporting, staff coordination, and day-to-day development. The role will also include building a PEM structure capable of handling both advanced collaborative academic studies and the most demanding preclinical projects performed in GLP-like or, where relevant, GLP-compatible quality frameworks.
The ideal candidate will be an accomplished scientist with broad experience in translational biomedical research and preclinical evaluation, and with the intellectual range to connect different analytical and biological disciplines into one functional module. This may include expertise in pathology, pharmacology, immunology, metabolism, toxicology, biomarker research, or other areas relevant to preclinical assessment.
This role is particularly suitable for a person who is comfortable operating at the interface of science, study design, infrastructure services, and client-oriented project execution. Beyond scientific credibility, the successful candidate should bring leadership maturity, organisational confidence, and the ability to shape PEM into a trusted platform for both internal CCP projects and external collaborations, including projects with industry.
The PEM is expected to include not only specialist analytical units but also dedicated functions supporting high-level study execution and quality assurance. These are expected to include a Head of Preclinical Studies (or equivalent study-lead role) responsible for coordination of complex studies, as well as a Quality Manager / GLP specialist supporting quality systems, QA interaction, documentation standards, and readiness for the most demanding client-facing projects.
This is a long-term position. The initial appointment will be for one year and may be extended based on mutual agreement and successful performance, with the possibility of an indefinite appointment after subsequent extensions, in accordance with Czech labour legislation.
The expected start date is by agreement.
Eligible applications will be reviewed by a selection committee in accordance with the recruitment procedures of the Institute of Molecular Genetics of the Czech Academy of Sciences. Candidates selected for the next stage will be invited to an in-person interview.
Applicants are invited to submit:
Applications should be submitted electronically to Jana Šafránková at jana.safrankova@img.cas.cz by 15 November 2026.
For informal enquiries about the position, applicants may use the same contact email address.
For more information about CCP, please visit www.phenogenomics.cz.